Latest Breaking News On - Kinghorn cancer centre - Page 1 : comparemela.com

IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma

~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage (maximum.

IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30.

APCCC 2024: Hot Flushes – How Can We Help Our Patients?

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting.

Skincare for cancer patients promoted by La Roche-Posay through Fight with Care campaign

Singer and survivor Delta Goodrem is promoting the skincare needs of cancer patients with a French beauty brand.